Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
37 studies found for:    Study of MK-3475
Show Display Options
Rank Status Study
1 Recruiting Study of MK-3475 (Pembrolizumab) in Participants With Advanced Melanoma (MK-3475-041)
Condition: Melanoma
Intervention: Biological: pembrolizumab
2 Recruiting Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer;   MSI Positive Non-Colorectal Cancers
Intervention: Drug: MK-3475
3 Not yet recruiting A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: MK-3475;   Drug: Azacitidine
4 Recruiting Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
Intervention: Biological: pembrolizumab
5 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
Conditions: Cancer;   Solid Tumor
Intervention: Drug: Pembrolizumab
6 Recruiting Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pemetrexed
7 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Condition: Solid Tumor
Intervention: Biological: Pembrolizumab
8 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
Condition: Non-small Cell Lung Cancer
Intervention: Biological: Pembrolizumab
9 Not yet recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Merkel Cell Carcinoma;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
10 Active, not recruiting Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)
Condition: Malignant Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Dacarbazine;   Drug: Temozolomide
11 Recruiting Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IIB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
12 Not yet recruiting Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
Condition: Advanced GI Cancer
Intervention: Drug: MK-3475
13 Recruiting MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Conditions: Melanoma;   Non-Small Cell Lung Cancer;   Brain Metastases
Intervention: Drug: MK-3475
14 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
15 Recruiting Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Conditions: Solid Tumor;   Non-small Cell Lung Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel
16 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Condition: Cancer, Solid Tumor
Interventions: Drug: Pembrolizumab 1 mg/kg;   Drug: Pembrolizumab 3 mg/kg;   Drug: Pembrolizumab 10 mg/kg;   Drug: Pembrolizumab MEL;   Drug: Pembrolizumab NSCLC;   Drug: Pembrolizumab MEL Low Dose;   Drug: Pembrolizumab MEL High Dose;   Drug: Pembrolizumab NSCLC Low Dose;   Drug: Pembrolizumab NSCLC High Dose;   Drug: Pembrolizumab NSCLC Medium Dose
17 Recruiting A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Condition: Advanced Solid Tumors
Interventions: Drug: PF-05082566;   Drug: MK-3475
18 Recruiting Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Gemcitabine
19 Recruiting A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Condition: Melanoma
Interventions: Biological: Pembrolizumab;   Drug: Dabrafenib;   Drug: Trametinib
20 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Condition: Multiple Myeloma
Interventions: Biological: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Indicates status has not been verified in more than two years